Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Budget Request Is Flat For Drugs, Pressuring Stakeholders

Executive Summary

Industry and advocates will have to take up fight for more CDER funding after Obama depends entirely on fees for human drugs program budget increase.

Advertisement

Related Content

US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security
A Hiring Freeze By A Different Name: OMB Wants Agency 'Workforce Reduction' Plans
FDA's No Comment On Budget Plans Leaves Awkward Void
Trump's Budget Outline Threatens User Fee Agreements
Off-Label Communication Growth: Could FDA Afford To Police It?
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
FDA Mutual Reliance With EU On Inspections Is Slow Going

Topics

Advertisement
UsernamePublicRestriction

Register

PS057450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel